A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (TEMPO-1 TRIAL)
Clinical Trial Grant
Administered By
Neurology, Movement Disorders
Awarded By
Cerevel Therapeutics
Start Date
September 24, 2020
End Date
December 31, 2024
Administered By
Neurology, Movement Disorders
Awarded By
Cerevel Therapeutics
Start Date
September 24, 2020
End Date
December 31, 2024